9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. BDRX, SHPH, ADTX, TRIB, DRMA, REVB, SPRC, ARTL, INDP, and ARAVShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Biodexa Pharmaceuticals (BDRX), Shuttle Pharmaceuticals (SHPH), Aditxt (ADTX), Trinity Biotech (TRIB), Dermata Therapeutics (DRMA), Revelation Biosciences (REVB), SciSparc (SPRC), Artelo Biosciences (ARTL), Indaptus Therapeutics (INDP), and Aravive (ARAV). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors Biodexa Pharmaceuticals Shuttle Pharmaceuticals Aditxt Trinity Biotech Dermata Therapeutics Revelation Biosciences SciSparc Artelo Biosciences Indaptus Therapeutics Aravive 9 Meters Biopharma (NASDAQ:NMTR) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Is NMTR or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Biodexa Pharmaceuticals N/A N/A N/A Do institutionals and insiders believe in NMTR or BDRX? 22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer NMTR or BDRX? Given 9 Meters Biopharma's higher possible upside, equities research analysts clearly believe 9 Meters Biopharma is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media prefer NMTR or BDRX? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Biodexa Pharmaceuticals and 0 mentions for 9 Meters Biopharma. Biodexa Pharmaceuticals' average media sentiment score of 0.95 beat 9 Meters Biopharma's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral Biodexa Pharmaceuticals Positive Which has better earnings and valuation, NMTR or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/ABiodexa Pharmaceuticals$470K10.39-$7.32MN/AN/A Which has more volatility and risk, NMTR or BDRX? 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. SummaryBiodexa Pharmaceuticals beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$225.72M$6.05B$10.45BDividend YieldN/A3.81%5.73%4.79%P/E Ratio0.0099.1785.9727.03Price / SalesN/A5,937.73582.52186.40Price / CashN/A13.1925.7330.17Price / BookN/A106.9612.686.68Net Income-$43.77M-$90.99M$3.31B$276.12M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020BDRXBiodexa Pharmaceuticals0.2754 of 5 stars$6.65-0.6%N/A-82.5%$4.12M$470K0.0020SHPHShuttle Pharmaceuticals0.7084 of 5 stars$3.55-6.6%N/A-85.4%$3.80MN/A-0.865Positive NewsADTXAditxtN/A$0.75-8.8%N/A-99.8%$3.75M$130K0.0060Positive NewsTRIBTrinity Biotech1.4794 of 5 stars$1.04-1.0%N/A-89.5%$3.74M$61.56M-0.07480Positive NewsDRMADermata Therapeutics2.7692 of 5 stars$5.02-3.5%$10.00+99.2%-69.3%$3.41MN/A-0.318Positive NewsREVBRevelation Biosciences1.5772 of 5 stars$1.42-0.7%N/A-96.4%$3.32MN/A-0.0210Positive NewsSPRCSciSparc0.8303 of 5 stars$6.04+35.4%N/A-14.9%$3.23M$1.31M0.004Gap UpHigh Trading VolumeARTLArtelo Biosciences2.9661 of 5 stars$4.59-21.5%$24.00+422.9%-32.3%$3.21MN/A-0.245Gap DownINDPIndaptus Therapeutics2.0928 of 5 stars$2.87-4.0%$238.00+8,192.7%-89.0%$3.18MN/A-0.086ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading Volume Related Companies and Tools Related Companies BDRX Alternatives SHPH Alternatives ADTX Alternatives TRIB Alternatives DRMA Alternatives REVB Alternatives SPRC Alternatives ARTL Alternatives INDP Alternatives ARAV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
